A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

Clinical trial NCT06905275 · SUSPENDED

Trial details

NCT number: NCT06905275
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Status: SUSPENDED
Phase: Phase 1
Study type: INTERVENTIONAL

HIV-1-infection

Start date: 2025-07-07
Primary completion: 2027-07-20
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.